International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 009-015
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
The Role of 18F-FDG PET/ CT in Follow up of Advanced Stage Breast Cancer
Nalan CAN1, L. Özlem KAPUCU2, Aytuğ ÜNER3, Mustafa ÜNLÜ2
1Visart Tıbbi Görüntüleme Merkezi
2Gazi Üniversitesi Tıp Fakültesi Nükleer Tıp Anabilim Dalı, ANKARA
3Gazi Üniversitesi Tıp Fakültesi Dahiliye Anabilim Dalı, Medikal Onkoloji Bölümü, ANKARA
Keywords: Breast, Metastasis, 18F-FDG, PET/ CT
We studied the role of 18F-FDG PET/ CT in the follow up of advanced stage breast cancer in comparison with clinical parameters, tumor markers (CEA, CA15-3) and bone scan findings.
Twenty-six female patient with breast cancer (mean age 50 ± 9; 17 patients with stage IIIA, 3 with stage IIIB and 6 with stage IV) were referred for the PET scan due to raised tumor markers (11) and high clinical risk (15). All patients had blood level of tumor markers, bone scan and PET/ CT scan in 3 months.
In the PET/ CT scan, 46% of the patients (12/26) had progression. Eight of these cases were progressed from stage IIIA/ B to stage IV. Three of patients with progression having high tumor marker had normal bone scan findings. Metastatic bone scan findings were detected in 35% of patients (27 metastatic lesion). In the PET/ CT scan, the number of pathological bone activity (probably metastatic) was 45. Six patients with suspicious metastatic findings in bone scan had normal PET/ CT scan. Eight cases with progression had pathological extraskeletal findings in the PET/ CT scan (20 visceral lesion).
For restaging of the breast cancer patients, 18F-FDG PET scan is more reliable than bone scan and tumor markers, and more accurate to detect disease progression.
Nalan CAN1, L. Özlem KAPUCU2, Aytuğ ÜNER3, Mustafa ÜNLÜ2
1Visart Tıbbi Görüntüleme Merkezi
2Gazi Üniversitesi Tıp Fakültesi Nükleer Tıp Anabilim Dalı, ANKARA
3Gazi Üniversitesi Tıp Fakültesi Dahiliye Anabilim Dalı, Medikal Onkoloji Bölümü, ANKARA
Keywords: Breast, Metastasis, 18F-FDG, PET/ CT
We studied the role of 18F-FDG PET/ CT in the follow up of advanced stage breast cancer in comparison with clinical parameters, tumor markers (CEA, CA15-3) and bone scan findings.
Twenty-six female patient with breast cancer (mean age 50 ± 9; 17 patients with stage IIIA, 3 with stage IIIB and 6 with stage IV) were referred for the PET scan due to raised tumor markers (11) and high clinical risk (15). All patients had blood level of tumor markers, bone scan and PET/ CT scan in 3 months.
In the PET/ CT scan, 46% of the patients (12/26) had progression. Eight of these cases were progressed from stage IIIA/ B to stage IV. Three of patients with progression having high tumor marker had normal bone scan findings. Metastatic bone scan findings were detected in 35% of patients (27 metastatic lesion). In the PET/ CT scan, the number of pathological bone activity (probably metastatic) was 45. Six patients with suspicious metastatic findings in bone scan had normal PET/ CT scan. Eight cases with progression had pathological extraskeletal findings in the PET/ CT scan (20 visceral lesion).
For restaging of the breast cancer patients, 18F-FDG PET scan is more reliable than bone scan and tumor markers, and more accurate to detect disease progression.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |